The findings are discussed in terms of the fact that self-harm is a criterion for involuntary hospitalisation, and private facilities do not treat involuntary patients. Certain problems assessed by the HoNOS are more amenable to rapid reduction than others, and this may contribute to differences in length of stay. Implications for outcome measurement are discussed.

No abstract

The prevalence of idiopathic Parkinson's Disease (IPD) in Dunedin, New Zealand on 31st July 1990 was 110.4/100,000. When corrected to a standard population based on the 1960 U.S. census, the prevalence fell to 76.0/100,000 due to changes in the age structure of the population. The corrected prevalence in Wellington (another New Zealand city), in 1962 was 99.6 (before the introduction of levodopa), and in Aberdeen, Scotland in 1984 was 102.7. The principal difference was fewer people under 65 years of age in our study. Case finding methods and diagnostic criteria were similar in all three studies, and case ascertainment was adequate. Under representation of younger people could be due to either a lower incidence rate or poorer survival due to treatment with high doses of levodopa compounds. Prospective research is required to explain our findings.

Certain items, notably 11 and 12, were unreliable. The absence of evidence of sensitivity to change may be due to the short re-rating interval, little real change in the clients, or the characteristics of the scale itself.

Az alábbi dokumentumot magáncélra töltötték le az eLitMed.hu webportálról. A dokumentum felhasználása a szerzôi jog szabályozása alá esik. A major és minor depresszió prevalenciája Parkinson-kór-ban szenvedôk között körülbelül 30-40%, ugyanakkor a depresszió ebben a betegcsoportban aluldiagnosztizált és alulkezelt kórkép. A depresszió diagnózisának és az adekvát kezelésének elmaradása nemcsak a depressziós tünetek perzisztálásához, de csökkent életminôséghez, az alapbetegség súlyosabb tüneti képéhez és kedvezôtlenebb prognózisához is vezetnek. Összefoglaló tanulmányunkban a Parkinson-kórban megjelenô depresszió epidemiológiai, patofiziológiai és terápiás vonatkozásait tárgyaljuk. Kulcsszavak: depresszió, Parkinson-kór, rizikófaktor, epidemiológiaThe prevalence of major and minor depression in Parkinson's disease is around 30-40% but, unfortunately, depression remains frequently underrecognized and often undertreated. However, recognition and appropriate treatment of depression in patients with Parkinson's disease is essential for improving the cross-sectional picture and longitudinal course. This review focuses on the epidemiology, pathophysiology and different treatment modalities of depression in Parkinson's disease.